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Fig 1. FF-ANN scheme. 
 
Results: An inverse correlation of the radio-sensitivity 
parameter assessed by the model was found with respect the 
dR2* (-0.65) for the Oxy group. A further subdivision 
according to positive and negative values of dR2* showed a 
larger average radio-sensitivity for the Oxy rats with <0 and a 
significant difference in the two distributions according to 
the Wilcoxon-Mann-Whitney test (p<0.05). Finally, the 
Pearson correlation coefficient (R^2>0.9) revealed a strong 
agreement of the FF-ANN output with the target radio-
sensitivity. 
 
Conclusion: These preliminary findings support the 
hypothesis that the change in the R2* can be related to tumor 
oxygenation and, consequently, to its radio-sensitivity. In 
particular, the sign of the tendency is in accordance with the 
fact that an oxygenation increase reduces the tumor 
relaxation rate as reported in the literature. Moreover, the 
different distributions of α, outlined in the Oxy subgroups 
according to the dR2*, suggest that some subjects would 
benefit from oxygen inhalation more than others, reasonably 
due to their initial vascularization. Finally, the performance 
of the FF-ANN is promising, although it would require a larger 
dataset to validate its prediction ability. 
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Purpose or Objective: Administration of monoclonal 
antibody Epidermal Growth Factor Receptor (MoAb-EGFr) 
inhibitor every week during Radiotherapy (RT) of head and 
neck cancer (HNC) has shown improved outcomes as 
compared to RT alone in terms of locoregional disease 
control, progression free and overall survival, thanks to its 
radiosensitizing effect. MoAb-EGFr concentration varies day 
by day after injection, and radiosensitizing effect 
accordingly. A radiobiological (RB) model accounting for this 
variation (Pedicini, et al. Radiat Oncol. 2012;7:143) can be 
applied to shorten the treatment by optimizing daily RT dose, 
still maintaining unchanged the biological effect on the 
tumour (in terms of surviving cells) as compared to standard 
RT (7 weeks, PTV1: GTV, 70Gy; PTV2 = GTV+margin, 63Gy; 
PTV3: lymph nodes: 58.1Gy) and potentially reducing healthy 
tissue toxicity. In this study, such RB model was adopted in 
the clinical protocol FAMOSO (Frazionamento Accelerato 
MOdulato in SIB-IMRT dei tumori testa-collO) for the 
treatment of HNC tumours with simultaneous integrated 
boost (SIB), aiming to test the feasibility of accelerated 
modulated fractioning and to assess toxicity and response 
rate. 
 
Material and Methods: From literature data, showing that 
higher concentrations of MoAb-EGFr correspond to steeper 
tumor cell survival curves, radiobiological parameters were 
derived and included in the RB model to obtain the daily dose 
to be delivered to each target volume. To date, 2 of the 10 
expected pts (pt1: cT4cN1 oropharyngeal; pt2: cT2 cN3 
supraglottic squamous cell carcinoma) have been recruited 
and treated with SIB-IMRT with a curative intent. 
 
Results: The RB model suggested a 6 week treatment with 
daily increasing dose/fractions as follows: PTV1: 1.70, 1.95, 
2.15, 2.30, 2.35Gy; PTV2: 1.50, 1.75, 1.95, 2.05, 2.10Gy; 
PTV3: 1.40, 1.60, 1.80, 1.90, 1.95Gy. Both pts recruited in 
the FAMOSO protocol concluded the radiation treatment : pt1 
with no change of the planned schedule; pt2 with 
interruption of MoAb-EGFr after the 5th administration and, 
consequently, the last 10 RT fractions of RT were 
administered with standard fractionation. The total dose to 
the PTV1 were 62.7 and 61.8 Gy, respectively. Maximun 
acute skin and mucosal toxicity was G3. With a follow up of 6 
and 2 months, a partial response was obtained for pt1, while 
pt2 is still under evaluation. 
 
Conclusion: New treatment strategies, even accelerated, are 
feasible when combining RT with radiosensitizing drugs. The 
RB model is adequate to set up the treatment provided 
radiobiological parameters are available from clinical data. 
The preliminary clinical data of the protocol FAMOSO give 
encouraging results, suggesting that the treatment schedule 
is feasible with acceptable acute toxicity. Longer follow up is 
needed to confirm toxicity findings and assess response rate, 
and of course more patients have to be studied. 
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Purpose or Objective: Variability in the contouring of gross 
tumour and the derived planning target volumes (PTVs) 
between clinicians is well-known in radiotherapy. This study 
aims to quantify the impact of variability in contouring in 
terms of tumour control and normal tissue toxicity in Liver 
SBRT. 
 
Material and Methods: The National Radiotherapy Trials 
Quality Assurance (RTTQA) Group planning benchmark case 
for the ABC07 Trial was used (addition of stereotactic body 
radiotherapy to systemic chemotherapy in locally advanced 
biliary tract cancers; CRUK A18752, sponsor University 
College London). 12 centers performed contouring 
independently using radiotherapy trial protocol as per RTTQA 
pre-trial QA process. Each centre applied margins to derive 
PTV as per local practice. A standardised Volumetric 
Modulated Arc Therapy (VMAT) plan was produced based on 
gold standard contours and applied to all 12 sets of submitted 
contours aiming to deliver 50Gy in 5 fractions. However, due 
to large GTV this was unavoidably de-escalated to 40Gy to 
meet trial mandatory mean non-GTV Liver constraint. 
Tumour control was assessed through biologically effective 
dose (BED) to 98, 95 and 90% of the gold standard PTV. 65Gy 
BED, although disappointingly low for SBRT, was considered 
ESTRO 35 2016                                                                                                                                                    S805 
________________________________________________________________________________ 
as a cut off for acceptable therapeutic intent. NTCP modeling 
of radiation induced Liver disease was also performed. 
 
Results: Non-GTV Liver mean dose ranged from 13.1 to 
17.0Gy, breaching mandatory trial constraint of <15.2Gy in 
three cases. NTCP ranged from 0.0 to 0.3 assuming an 
alpha/beta of 1.0 for normal Liver and negligible assuming 
alpha/beta of 2.0 or more. At D98%, four sets of contours did 
not achieve 65Gy BED to gold standard PTV, two sets failing 
to reach 65Gy BED at D90%.  
 
Conclusion: Significant variability exists in contours drawn by 
different centers/clinicians in the setting of pre-trial QA to 
the extent where 10% or more of the PTV receives a BED 
insufficient for local control in a proportion of cases and 
NTCP is significantly affected. Given this variability, the pre-
trial and on-trial RTTQA process is essential if the effect of 
contour variability on tumour control rates and treatment 
toxicity is to be mitigated.  
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Purpose or Objective: To use spatial features from dose 
surface maps of the duodenum to predict acute duodenal 
related toxicity in pancreatic chemoradiation. 
 
Material and Methods: Dose surface maps were produced for 
the duodenum describing the spatial surface dose 
distribution. Traditional metrics were extracted including 
mean and max dose, surface area receiving 25, 35, 45 and 55 
Gy as absolute and fraction of the surface. Spatial metrics 
extracted include the length of the duodenum which received 
less than 25, 35, 45 and 55 Gy to at least 10-90% of the 
circumference (in 10% intervals). Different thresholds for the 
length of the duodenum achieving these constraints were 
tested in order to find the best predictor of toxicity. Toxicity 
results from 19 patients from the ARCII clinical trial 
(EudraCT: 2008-006302-42) were used as a proof of concept. 
6 and 11 patients had grade (Gr) ≥3 and Gr ≥2 toxicity 
respectively.  
 
Results: The best predictors for patients with grade (Gr) ≥3 
toxicity were at higher doses of 55 Gy. While restricting the 
dose < 55 Gy to at least 10% of the circumference for at least 
10% of the length of the duodenum, or at least 20% of the 
circumference for at least 20% of the length accurately 
predicted toxicity for 74% of the patients studied, this only 
had a sensitivity of 17% and 33% respectively (specificity of 
100% and 92%). Figure 1 indicates a better predictor may be 
restricting dose < 55 Gy to at least 20% of the circumference 
for at least 70% of the length which, although only accurately 
predicts toxicity for 58% of the patients, has a sensitivity and 
specificity of 67% and 54%. It was found that the relative 
percentage of the circumference spared was a better 
predictor than absolute circumferential length spared. 
However, similarly to the spatial metrics, predictions of 
patients with at least Gr 3 toxicity was seen in the higher 
dose regions such as mean dose of 60 Gy, maximum dose to a 
pixel of 62 Gy and when 70% of the surface area receives 55 
Gy. Gr 2 toxicity could not be predicted. 
 
 
 
Conclusion: In this small sample we have shown that spatial 
features can be extracted from dose surface maps to aid 
toxicity prediction, and that high doses to the duodenum 
appear to be correlated with Gr 3 toxicity. An improved 
understanding of how these spatial features correlate to 
toxicity can improve traditional constraints on the 
duodenum. Further work is required to build a more 
complete picture of this result, and the analysis will now be 
extended to a larger patient cohort. 
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Purpose or Objective: In a previous work a model which 
simulates the radiation response of hypoxic tumors was 
developed. The task of this work is to validate the model by 
using preclinical experimental dose response data of rat 
prostate tumors for single and multiple irradiations. 
 
Material and Methods: The model is voxel-based and 
simulates the spatio-temporal behavior of tumors considering 
six radio-biological processes. Important input data are the 
oxygenation levels of each tumor subvolume at the time of 
irradiation, which are given as pre-calculated oxygen 
frequency histograms.The experimental data for validation 
include growth curves, dose response curves and TCD50s for 
1, 2 and 6-fraction (Fx) experiments. A very high α/β value of 
84.7 ± 13.8 Gy was determined.A strategy of adjustment was 
